Clinical Trial

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-22.
Trial Details
NCT Number NCT07673744
Lead Sponsor TG Therapeutics, Inc.
Conditions Myasthenia Gravis
Enrollment 120 participants
Start Date 2026-07-30
Primary Completion 2028-07-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17